Humacyte Inc (NASDAQ:HUMA) has a beta value of 1.45 and has seen 2.11 million shares traded in the last trading session. The company, currently valued at $717.45M, closed the last trade at $5.73 per share which meant it gained $0.18 on the day or 3.24% during that session. The HUMA stock price is -74.0% off its 52-week high price of $9.97 and 65.79% above the 52-week low of $1.96. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.03 million shares traded. The 3-month trading volume is 3.10 million shares.
The consensus among analysts is that Humacyte Inc (HUMA) is Buy stock at the moment, with a recommendation rating of 1.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 2 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.25.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Humacyte Inc (NASDAQ:HUMA) trade information
Sporting 3.24% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the HUMA stock price touched $5.73 or saw a rise of 1.38%. Year-to-date, Humacyte Inc shares have moved 101.76%, while the 5-day performance has seen it change 5.33%. Over the past 30 days, the shares of Humacyte Inc (NASDAQ:HUMA) have changed 1.96%. Short interest in the company has seen 16.03 million shares shorted with days to cover at 6.28.
Wall Street analysts have a consensus price target for the stock at $4.5, which means that the shares’ value could drop -27.33% from current levels. The projected low price target is $4.0 while the price target rests at a high of $5.0. In that case, then, we find that the current price level is 12.74% off the targeted high while a plunge would see the stock lose 30.19% from current levels.
Humacyte Inc (HUMA) estimates and forecasts
Figures show that Humacyte Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 98.96% over the past 6 months, with this year growth rate of -1.87%, compared to 17.40% for the industry.
5 have an estimated revenue figure of 420k for the next ending quarter.
HUMA Dividends
Humacyte Inc is expected to release its next earnings report on 2024-Nov-07 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
Insiders own 27.91% of the company shares, while shares held by institutions stand at 25.50% with a share float percentage of 35.37%. Investors are also buoyed by the number of investors in a company, with Humacyte Inc having a total of 168.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 7.14 million shares worth more than $34.27 million. As of 2024-06-30, BLACKROCK INC. held 6.5961% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 4.73 million shares as of 2024-06-30. The firm’s total holdings are worth over $22.7 million and represent 4.3693% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund . As of Aug 31, 2024 , the former fund manager holds about 2.01% shares in the company for having 2.4 shares of worth $13.75 million while later fund manager owns 2.39 shares of worth $13.68 million as of Jun 30, 2024 , which makes it owner of about 2.00% of company’s outstanding stock.
